Cargando…

The role of lumateperone in the treatment of schizophrenia

Schizophrenia is a devastating mental disorder resulting in marked morbidity and mortality despite the optimal use of all currently available interventions. For this reason, the release of lumateperone (Captyla(R)), also known as ITI-007, an orally administered, atypical antipsychotic provided a wel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Syed, Alveena Batool, Brašić, James Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326816/ https://www.ncbi.nlm.nih.gov/pubmed/34377435 http://dx.doi.org/10.1177/20451253211034019

Ejemplares similares

Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
por: Vanover, Kimberly E., et al.
Publicado: (2018)

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial
por: Correll, Christoph U., et al.
Publicado: (2020)

T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS
por: Durgam, Suresh, et al.
Publicado: (2020)

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials
por: Kane, John M, et al.
Publicado: (2021)

S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY
por: Vanover, Kimberly, et al.
Publicado: (2018)

Illuminating Hope for Mental Health: A Drug Review on Lumateperone
por: Tarzian, Martin, et al.
Publicado: (2023)

S221. THE EFFICACY OF LUMATEPERONE 42 MG IN THE TREATMENT OF SCHIZOPHRENIA SYMPTOMS ASSOCIATED WITH SOCIAL FUNCTIONING: POST HOC ANALYSIS OF AN ACUTE PLACEBO- AND ACTIVE-CONTROLLED TRIAL
por: Vanover, Kimberly, et al.
Publicado: (2020)

New synthesis of a late-stage tetracyclic key intermediate of lumateperone
por: Milen, Mátyás, et al.
Publicado: (2022)

Management of subjects with Intermittent Explosive Disorder and Autism Spectrum Disorder with Lumateperone
por: Mehdiratta, N., et al.
Publicado: (2023)

Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?
por: Barman, Rajdip, et al.
Publicado: (2021)

Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation
por: Dutheil, Sophie, et al.
Publicado: (2023)

F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
por: Davis, Robert, et al.
Publicado: (2018)

Atypical Antipsychotic Lumateperone Effects on the Adrenal Gland With Possible Beneficial Effect of Quercetin Co-administration
por: El-Haroun, Hala, et al.
Publicado: (2021)

M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY
por: Satlin, Andrew, et al.
Publicado: (2020)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome, Leslie
Publicado: (2011)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb, Nilufar, et al.
Publicado: (2012)

The Role of Estrogen in the Treatment of Men with Schizophrenia
por: Kulkarni, Jayashri, et al.
Publicado: (2013)

Reply to Aljabali et al. Comment on “Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina 2022, 58, 213”
por: Abdelazeem, Basel, et al.
Publicado: (2022)

Dataset of quantitative structured office measurements of movements in the extremities
por: Harrigan, Timothy P., et al.
Publicado: (2020)

The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Abbas, Kirellos Said, et al.
Publicado: (2022)

Role of Melatonin in Schizophrenia
por: Morera-Fumero, Armando L., et al.
Publicado: (2013)

The Role of Oestrogen and Other Hormones in the Pathophysiology and Treatment of Schizophrenia
por: Hayes, Emily, et al.
Publicado: (2012)

Contact Force-Guided versus Contact Force-Blinded Cavo-Tricuspid Isthmus Ablation for Atrial Flutter: A Systematic Review and Meta-Analysis
por: Abuelazm, Mohamed, et al.
Publicado: (2023)

An Unusual Case of Parasitic Constrictive Pericarditis
por: Agrawal, Ankit, et al.
Publicado: (2023)

The Role of Cytokines in the Pathogenesis of Schizophrenia
por: Dawidowski, Bartosz, et al.
Publicado: (2021)

The Role of Inflammation in the Treatment of Schizophrenia
por: Fond, Guillaume, et al.
Publicado: (2020)

Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Mahmoud, Abdelrahman, et al.
Publicado: (2022)

The Effect of Vitamin D Supplementation on the Severity of Symptoms and the Quality of Life in Irritable Bowel Syndrome Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Abuelazm, Mohamed, et al.
Publicado: (2022)

The Role of D-Serine and D-Aspartate in the Pathogenesis and Therapy of Treatment-Resistant Schizophrenia
por: Nasyrova, Regina F., et al.
Publicado: (2022)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
por: Maksymetz, James, et al.
Publicado: (2017)

Pharmacotherapy for treatment-resistant schizophrenia
por: Mcilwain, Meghan E, et al.
Publicado: (2011)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin, Tomomi, et al.
Publicado: (2013)

The Pharmacological Shock Treatment of Schizophrenia
Publicado: (1938)

Current Concepts and Treatments of Schizophrenia
por: Stępnicki, Piotr, et al.
Publicado: (2018)

A low-cost quantitative continuous measurement of movements in the extremities of people with Parkinson's disease
por: McKay, Gregory Neal, et al.
Publicado: (2019)

Research Trends of Vitamin D Metabolism Gene Polymorphisms Based on a Bibliometric Investigation
por: Abouzid, Mohamed, et al.
Publicado: (2023)

Recent Advances in EPAC-Targeted Therapies: A Biophysical Perspective
por: Ahmed, Alveena, et al.
Publicado: (2019)

Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review
por: Arroll, Megan Anne, et al.
Publicado: (2014)

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
por: McCutcheon, Robert A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bajvncen89tch9ai8vtr44dsa3